Explore how AI accelerates antibody discovery by enabling de novo design, epitope prediction, and in silico affinity maturation for highly specific, developable therapeutics.
Learn how deep learning and structure-based models optimize antibody stability, immunogenicity and target binding to advance precision biologics.
Sponsor(s):
Cradle Bio B.V.
Speaker(s):
Eli Bixby
CoFounder & Head of ML
Cradle Bio B.V.
Eli makes sure Cradle's models and algorithms are doing what we think they are doing, and he keeps an eye out for the latest and greatest techniques in the literature. He was previously at Google (Brain, Accelerated Science, Cloud) working on biological sequence design, AutoML, and natural language understanding. He studied mathematics, computer science, and biochemistry
Claudette Fuller
Vice President, Non Clinical Safety & Toxicology
Genmab
Gevorg Grigoryan
Co-Founder & CTO
Generate Biomedicines
Time:
3:30 PM - 4:00 PM
Agenda Track No.:
Track 1
Session Type:
General Session (Presentation)